Previous 10 | Next 10 |
Ambow Education (AMBO) -17%.Oxbridge Re (OXBR) -13%.The Peck Company (PECK) -12%.Ironwood Pharmaceuticals (IRWD) -12% on terminating development of IW-3718 for refractory gastroesophageal reflux disease.Urban One (UONE) -11%.Professional Diversity Network (IPDN) -10%....
Based on assessment of independent data monitoring committee, Ironwood Pharmaceutical (IRWD) announces that it will terminate development of IW-3718 for refractory gastroesophageal reflux disease ((GERD)).In IW-3718-302, one of its identical Phase 3 trial of IW-3718, ...
– Trial did not achieve statistically significant improvement in heartburn severity (primary endpoint) – – Ironwood plans to implement organizational restructuring, resulting in expected headcount reduction of approximately 100 full-time employees, or near...
A catalyst is expected for Ironwood, in that it expects an IDMC decision for its phase 3 study IW-3718-302 using IW-3718 to treat patients with refractory GERD Q4 2020. The GERD market is expected to be roughly about $4.34 billion by 2025. Prescription demand for Linzess was up 9%...
Although many stocks trade below $10 per share, some deserve that price more than others. Many will remain stuck at that level, while some go on to produce massive growth. AMD is on fire after falling into penny-stock status five years ago. And at the low point of the dot-com bust, even...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in fireside chats at two upcoming virtual investor conferences in September: 2020 Wells Fargo Virtual Healthcare Conference on Wednesday, September 9, 2020 at 11:20 a.m. ET Morgan Stanley Virtual 18th Annual Global Hea...
Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2020 Earnings Conference Call August 6, 2020 08:30 am ET Company Participants Meredith Kaya - Vice President, Investor Relations and Corporate Communications Mark Mallon - Chief Executive Officer Tom McCourt - President Gina Consylman - ...
Image source: The Motley Fool. Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Q2 2020 Earnings Call Aug 7, 2020 , 8:30 p.m. ET Operator Continue reading
The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Ironwood Pharmaceuticals (NASDAQ: IRWD ) : Q2 Non-GAAP EPS of $0.16 beats by $0.06 ; GAAP EPS of $0.16 beats by $0.08 . More news on: Ironwood Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...